Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

MediWound Ltd. MDWD

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.14
Total sells
0.08
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — 1 2 — — —
Sell — — — — — — — — — — 1 1
Insider Ownership
25.33%

Capital & Financial Ratios

Market Cap
172.35
Revenue
11.86
Net Income
(20.18)
Free Cash Flow
(28.53)
Net Debt
(35.34)
Current Ratio
2.32
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
14.55
P/B ratio
4.84
Past 5Y EPS Growth
(22.25%)
This Y EPS Growth
(4.35%)
Next Y EPS Growth
(0.31%)
Next 5Y EPS Growth
16.86%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 41.71 43.16 53.14 35.34
Receivables 5.14 6.31 2.73 3.49
Inventory 2.85 2.69 4.09 4.12
Other — — — —
49.70 52.16 59.96 42.95
2023 2024 2025 Q'26
Payables 5.53 5.28 7.65 7.63
ST’ Debt — — — —
Other 8.71 17.70 13.53 5.67
18.13 26.54 25.71 18.54
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 1.48 3.09 — —
—
’25 3.96 5.71 5.43 1.87
16.96
’24 4.96 5.06 4.36 5.84
20.22
’23 3.80 4.77 4.78 5.34
18.69
’22 4.41 4.67 5.80 11.62
26.50
’21 5.85 6.06 6.37 5.49
23.76
’20 4.44 4.03 6.63 6.67
21.76
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (6.75) (9.13) — —
—
’25 (4.11) (5.76) (3.24) (3.02)
(16.12)
’24 (4.61) (3.62) (3.76) (1.64)
(13.62)
’23 0.65 (5.25) (3.25) (2.61)
(10.46)
’22 (4.06) (5.25) (4.57) 2.00
(11.88)
’21 (2.91) (0.95) (2.82) (2.23)
(8.92)
’20 (1.80) (2.81) 1.04 (3.32)
(6.89)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (8.57) (10.20) — —
—
’25 (5.07) (6.80) (4.28) (5.47)
(21.63)
’24 (5.87) (6.64) (4.95) (2.44)
(19.90)
’23 (0.85) (6.32) (4.94) (4.82)
(16.93)
’22 (4.22) (5.39) (4.65) 1.83
(12.44)
’21 (3.13) (0.98) (2.95) (2.35)
(9.40)
’20 (1.95) (2.91) 0.80 (3.76)
(7.82)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.23) (0.77) — —
—
’25 (0.07) (1.23) (0.24) (0.56)
(2.10)
’24 (1.05) (0.68) (0.98) (0.36)
(3.03)
’23 (0.44) 0.10 (0.24) (0.19)
(0.75)
’22 (0.84) (0.91) (0.91) (1.18)
(3.93)
’21 (0.70) (0.84) (0.84) (1.05)
(3.50)
’20 (0.63) (0.77) (0.49) (0.42)
(2.38)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 8.05 7.10 10.20 14.14 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 23.66 14.58 24.00 22.51 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 83 88 111 121 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.32 0.21 0.18 0.14 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 26.50 18.69 20.22 16.96 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 49.69% 19.15% 13.03% 19.19% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (19.52) (6.53) (30.16) (23.71) — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (73.68%) (34.95%) (149.16%) (139.81%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (19.60) (6.72) (30.22) (23.88) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.27 1.30 1.48 1.86 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.31 2.07 2.03 1.49 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.93) (0.75) (3.03) (2.10) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.38) (1.16) (1.37) (1.42) — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.11) (0.72) (0.63) (0.48) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.49) (1.88) (2.00) (1.90) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.19 3.51 3.13 3.84 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.99 9.01 9.96 11.38 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.50 5.43 8.77 12.38 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ 6.07 3.21 5.69 4.81 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.27 3.63 6.96 9.65 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.70) (3.99) (7.06) (7.55) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (11.88) (10.46) (13.62) (16.12) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.55) (6.46) (6.27) (5.50) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (12.44) (16.93) (19.90) (21.63) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 33.78 31.57 25.62 34.26 — — —
Working Cap'
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.38 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (32.52) (41.71) (43.16) (53.14) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.91 31.60 31.15 43.63 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (56.19%) (11.53%) (43.19%) (29.90%) — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (619.05%) (31.60%) (96.33%) (63.86%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

MediWound Ltd. (MDWD), an Israeli biopharma player in enzymatic wound debridement, has shown flashes of promise with NexoBrid’s revenue surging 936% to a 2019 peak after European approval, but chronic unprofitability, plummeting gross margins from 63% to 13%, and aggressive share dilution (up 155% since 2019) have crushed shareholder value. The stock, down 63-76% from 2016-2017 highs despite 1,200% cumulative revenue growth, reflects investor doubts amid negative EPS (-$3.03 in 2024), deepening losses ($30M in 2024), and free cash flow burns (-$20M).

The 2023 FDA approval for NexoBrid in U.S. burns sparked a modest 2024 revenue uptick to $20M and partial stock recovery, yet R&D/SG&A costs outpace gains, with efficiency metrics like revenue per employee down 58%. Analysts forecast a 2025 revenue dip to $17M before rebounding to $33M by 2027 on U.S. ramp-up and EscharEx trials, but predict prolonged losses (-$30M+ annually) and further dilution to 12.8M shares.

At elevated PS ratios (8.8x) and EV/Sales (7x), targets imply 45-125% upside, tempting speculators, but cash burn, margin erosion, regulatory risks, and Israel’s geopolitics loom large—making MDWD a high-stakes bet for monitoring U.S. sales and Phase 3 data, not conservative portfolios.

Read full commentary →

MediWound Ltd. (MDWD) Latest News

News by impact score

Fine-tune

14 Sep

3 , 7:00 AM
Independent DSMB recommends MediWound’s EscharEx Phase III VALUE study continue without modification. Positive DSMB review keeps EscharEx Phase III trial on track without delays.

20 Aug

4 transcript www.fool.com, 8:42 AM
MediWound Ltd. held its Q2 2026 earnings call, covering financial results, operational updates and forward outlook for the company. Earnings call details financial performance and strategic plans that can materially shift company trajectory and investor sentiment.

14 Aug

3 transcript app.moby.co, 8:30 AM
MediWound Ltd. released its Q2 2026 earnings call summary covering financial results and business updates. Quarterly earnings data can influence short-term stock movement and operational outlook without major strategic shifts.

13 Aug

4 transcript , 7:07 PM
MediWound Ltd reported record NexoBrid sales in Q2 2026 earnings call along with EscharEx development updates. Record NexoBrid sales and EscharEx progress point to major revenue growth and market expansion.

3 www.marketbeat.com, 2:04 PM
MediWound Ltd. released Q2 earnings call highlights covering financial results, operational updates and forward outlook. Quarterly earnings updates can shift near-term investor views and trading but rarely alter long-term company trajectory.

3 , 7:00 AM
MediWound Ltd. released second quarter 2026 financial results and a corporate update. Quarterly financial results can shift near-term investor views on performance and outlook.

28 May

3 transcript app.moby.co, 8:30 AM
MediWound Ltd. discussed its Q1 2026 financial results and operational updates during an earnings call. Quarterly earnings calls typically provide performance details that moderately influence near-term stock sentiment.

27 May

4 transcript GuruFocus.com, 5:00 PM
MediWound Ltd reported Q1 2026 earnings with focus on strategic collaborations and revenue performance. Strategic collaborations and revenue details from earnings call indicate major moves likely to shift company trajectory and investor views.

3 transcript www.fool.com, 2:34 PM
MediWound Ltd. (MDWD) released its Q1 2026 earnings call transcript covering financial results, operations and outlook. Quarterly earnings updates and guidance can moderately shift near-term financial views and stock sentiment.

3 transcript www.marketbeat.com, 10:06 AM
MediWound Ltd. released Q1 earnings call highlights covering financial results, operational updates and forward outlook. Q1 earnings details can move near-term stock price and sentiment but rarely alter long-term trajectory.

13 Apr

4 GlobeNewswire, 7:30 AM
Newly published U.S. expert consensus aligns with MediWound Ltd.'s strategy for chronic wound debridement. Expert consensus alignment validates MediWound's chronic wound debridement strategy, likely boosting investor sentiment and competitive positioning.

7 Apr

3 GlobeNewswire, 7:00 AM
MediWound Ltd. (MDWD) will present new EscharEx® data at leading wound care conferences. Presentation of new EscharEx data at conferences highlights product progress and could moderately influence investor sentiment and competitive positioning.

2 Apr

4 GlobeNewswire, 3:26 PM
MediWound Ltd. reports BARDA contract award to Vericel for NexoBrid®, valued at up to $197 million. BARDA contract up to $197 million for NexoBrid® provides significant revenue potential via partner Vericel, enhancing MediWound's financial outlook and market position.

5 Mar

4 app.moby.co, 12:35 PM
MediWound Ltd. (MDWD) released its Q4 2025 earnings call summary, highlighting financial results, operational updates, and future outlook for the wound care specialist. Q4 earnings call summary details financial performance and strategic updates poised to significantly sway MDWD's market trajectory and investor sentiment.

4 transcript www.fool.com, 11:27 AM
MediWound Ltd. (MDWD) released its Q4 2025 earnings call transcript, detailing financial results, operational updates, and forward-looking guidance. Q4 earnings call transcript discloses quarterly financials, strategic updates, and guidance that can drive substantial shifts in market performance and investor confidence.

4 GlobeNewswire, 7:00 AM
MediWound Ltd. (MDWD) reported fourth quarter and full year 2025 financial results. Full-year financial results directly affect MDWD's valuation, investor sentiment, and strategic trajectory.

3 www.marketbeat.com, 10:10 PM
MediWound Ltd. (MDWD) released Q4 earnings call highlights covering financial results, pipeline advancements, and strategic outlook. Q4 earnings highlights detail financial performance and operational updates with moderate influence on investor sentiment and trajectory.

3 Zacks, 8:20 AM
MediWound Ltd. (MDWD) reported a Q4 net loss and revenue below analyst estimates. Q4 loss and revenue miss highlight financial underperformance with moderate effects on stock sentiment and trajectory.

3 Associated Press Finance, 7:27 AM
MediWound Ltd. (MDWD) released Q4 earnings snapshot. Q4 earnings snapshot affects financial performance and market sentiment moderately.

28 Feb

4 www.marketbeat.com, 8:05 PM
MediWound Ltd. reports NexoBrid revenue growth, advances EscharEx Phase III trial timeline to start in Q1 2025, and progresses BARDA contract discussions at Oppenheimer Conference. NexoBrid growth, EscharEx Phase III acceleration, and BARDA talks represent major pipeline and funding advancements for MDWD.

12 Jan

3 GlobeNewswire, 7:00 AM
MediWound Ltd. provided a corporate update and financial outlook in anticipation of the J.P. Morgan Healthcare Conference. The company highlighted its strategic initiatives, ongoing clinical trials, and expected financial performance for the upcoming year, aiming to enhance investor confidence and market positioning. The corporate update and financial outlook may moderately influence investor sentiment and financial performance.

19 Dec

3 Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 7:54 AM
MediWound Ltd. (NASDAQ:MDWD) has garnered significant attention from institutional investors, who collectively own 52% of the company's shares. This strong institutional backing indicates confidence in MediWound's potential and may influence its market performance moving forward. Institutional ownership at 52% suggests a moderately noticeable influence on investor sentiment and market performance.

10 Dec

4 , 7:00 AM
MediWound Ltd. announced new clinical data demonstrating that NexoBrid® effectively prevents traumatic tattoos resulting from abrasion and blast injuries. This data highlights the product's potential in improving patient outcomes in severe burn cases, showcasing its role in wound care management. The findings are expected to enhance the product's market position and appeal to healthcare providers dealing with trauma-related injuries. The new clinical data could significantly enhance NexoBrid®'s market position and influence investor sentiment.

22 Nov

4 Simply Wall St., 7:20 AM
MediWound Ltd. is positioned for growth with its innovative product pipeline and strategic partnerships. The company focuses on developing advanced therapies for wound care, which are expected to enhance its market presence. Recent advancements and collaborations indicate a strong potential for revenue increase and market expansion, aligning with the company's long-term growth objectives. Strategic partnerships and product innovations are likely to significantly impact MediWound's future performance and market positioning.

20 Nov

4 GuruFocus.com, 4:00 PM
MediWound Ltd. (MDWD) reported a significant revenue surge in Q3 2025, driven by strategic expansions and increased demand for its products. The company highlighted its successful initiatives in enhancing market presence and product offerings, which contributed to improved financial performance. Management expressed optimism about future growth prospects and ongoing efforts to innovate within the industry. The revenue surge and strategic expansions are likely to significantly impact the company's future performance and investor sentiment.

3 Zacks, 8:10 AM
MediWound Ltd. (MDWD) reported a loss for Q3, falling short of revenue estimates. The company's financial performance has raised concerns among investors, as it continues to struggle with its market position and product offerings. Analysts are closely monitoring the situation to assess the potential long-term implications for the company's growth and stability. The missed revenue estimates and reported loss indicate challenges that may moderately affect financial performance and investor sentiment.

3 Associated Press FinanceAssociated Press FinanceAssociated Press FinanceAssociated Press FinanceZacks, 7:10 AM
MediWound Ltd. reported its Q3 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its innovative wound care products and ongoing clinical trials. Revenue figures and net income were disclosed, reflecting the company's performance during the quarter. Management provided insights into future growth strategies and market positioning, emphasizing the potential for product expansion and partnerships. The earnings report indicates moderate financial performance and strategic focus that may influence future operations.

3 GlobeNewswire, 7:00 AM
MediWound Ltd. reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its operations. The company provided updates on its product pipeline and strategic initiatives, indicating progress in its clinical trials and market positioning. Financial performance showed trends that may influence future growth, alongside insights into ongoing projects and collaborations. Financial results and updates on product pipeline suggest a moderate influence on future performance.

5 Nov

3 GlobeNewswire, 7:30 AM
MediWound Ltd. (MDWD) is set to report its financial results for the third quarter of 2025. The announcement is anticipated by investors and analysts, as it will provide insights into the company's performance and future outlook. The upcoming financial results may influence investor sentiment and provide insights into the company's operational performance.

3 Nov

4 , 8:00 AM
MediWound Ltd. has successfully completed the commissioning of its expanded GMP manufacturing facility for NexoBrid®, a product used for the treatment of severe burns. This expansion aims to enhance production capabilities and meet increasing demand. The facility is now fully operational, which is expected to support the company's growth and market presence in the biopharmaceutical sector. The completion of the expanded manufacturing facility is a significant strategic move that could enhance production capacity and market competitiveness.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us